SAN DIEGO, CA - April 23, 2025 (NEWMEDIAWIRE) - Quantumzyme Corp. (OTC: QTZM), a biotechnology company leveraging computational enzyme engineering, is pleased to announce the upcoming publication of its patent for an innovative enzymatic method to manufacture ibuprofen. Expected to be published in the coming months, the patent details a unique approach using a modified polypeptide that supports a more sustainable and efficient alternative to conventional production methods.
This enzymatic method represents a significant step forward in pharmaceutical manufacturing, offering a cleaner and more streamlined route to ibuprofen - one of the most commonly used nonsteroidal anti-inflammatory drugs (NSAIDs). By harnessing a specialized enzyme, the process reduces dependence on harsh chemicals and minimizes reaction steps, leading to better yields and a smaller environmental footprint.
“We’re looking forward to the publication of this patent, which reflects our continued focus on enabling greener solutions for complex chemical challenges,” said Naveen Kulkarni, CEO of Quantumzyme. “It’s a clear example of how enzyme-driven processes can be applied to improve efficiency and sustainability in pharmaceutical manufacturing.”
The publication will further solidify Quantumzyme’s position as a driving force in enzyme-based technology for the pharmaceutical sector. The company anticipates new licensing opportunities and a broader industry impact as it builds on its growing intellectual property portfolio.
“We are proud of the science behind this patent,” added Kulkarni. “It underscores the potential of enzyme innovation to reimagine essential manufacturing processes in a more responsible and scalable way.”
As the industry continues shifting toward environmentally conscious practices, Quantumzyme’s biocatalytic method positions itself as a compelling solution for future-ready API production.
For the most current information and updates, please visit our website at www.quantumzymecorp.com.
About Quantumzyme Corp.
Quantumzyme Corp. is a pioneering biotransformation company revolutionizing chemical processes through sustainable, enzyme-based solutions. Specializing in green chemistry, it harnesses quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to design high-performance biocatalysts that enhance efficiency, reduce waste, and minimize environmental impact. By integrating computational modeling with wet-lab validation, Quantumzyme delivers scalable, cost-effective biocatalysis solutions that improve industrial sustainability. Offering end-to-end enzyme development services - from discovery and engineering to process optimization and scale-up - Quantumzyme empowers its partners to adopt greener, more efficient production methods. Committed to sustainability and innovation, the company envisions a future where biotechnology drives global solutions for climate change, pollution, and resource efficiency, making eco-friendly biocatalysis the industry standard.
Disclaimer
The information contained in this press release is provided by Quantumzyme Corp. (“Quantumzyme”) for general informational purposes only. This release may include forward-looking statements that reflect Quantumzyme’s current expectations, estimates, projections, and assumptions about future events, business performance, market conditions, or technological developments. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. Forward-looking statements are based on management’s beliefs and assumptions as of the date of this press release and are subject to change without notice.
Quantumzyme makes no representations or warranties, express or implied, regarding the accuracy, completeness, or reliability of the information contained herein. The company undertakes no obligation to publicly update or revise any forward-looking statements as a result of new information, future developments, or changes in expectations, except as required by applicable law. Past performance should not be taken as an indicator of future results, and readers should not place undue reliance on any projections or expectations presented in this release.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor does it provide financial, investment, or legal advice. Any references to market trends, scientific advancements, or industry insights are provided for contextual purposes only and should not be interpreted as endorsements, guarantees, or definitive predictions of future developments. Readers and investors are encouraged to conduct their own due diligence and seek independent professional advice before making any investment or business decisions related to Quantumzyme or its affiliates.
Media Contact:
Naveen Kulkarni
Chief Executive Officer
Quantumzyme Corp.
15656 Bernardo Center Drive, Suite 801
San Diego, CA 92127
Phone: +1 (858) 203-0312
Email: info@quantumzymecorp.com
Website: www.quantumzymecorp.com
View the original release on www.newmediawire.com
